$7.260
-0.863 (-11.89%)Al cierre
Comparativa sectorial de EIKN
In the context of the broader market, EIKN competes directly with industry leaders such as INDP and SPRY. With a market capitalization of $393.24M, it holds a significant position in the sector. When comparing efficiency, EIKN's gross margin of N/A stands against INDP's N/A and SPRY's 61.83%. Such benchmarking helps identify whether Eikon Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Eikon Therapeutics Inc
Eikon Therapeutics has reported consistent net losses, with Q2 2026 showing a net income of -88,409,000. The EPS for Q2 2026 was -1.63, which is worse than the expected -1.61, indicating financial instability. The current ratio has been fluctuating, but it was 9.89 in Q2 2026, suggesting some liquidity.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.